JW Pharmaceutical Corporation

Total Valuation

JW Pharmaceutical Corporation carries a market capitalization of 399.06B, placing it among publicly traded companies globally. Its enterprise value stands at 1.29T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

JW Pharmaceutical Corporation currently has 22.55M shares outstanding.

Valuation Ratios

JW Pharmaceutical Corporation trades at a trailing price-to-earnings ratio of 18.17. The price-to-sales ratio is 1.65, and the price-to-book ratio stands at 4.57.

Enterprise Valuation

On an enterprise value basis, JW Pharmaceutical Corporation trades at an EV/EBITDA multiple of 12.18 and an EV/FCF ratio of 10.79. The EV/Sales ratio of 1.63 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 12.18 provides insight into valuation relative to core operating earnings.

Financial Position

JW Pharmaceutical Corporation maintains a current ratio of 1.46, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.

Financial Efficiency

JW Pharmaceutical Corporation posts a return on equity of 27.87 and a return on invested capital of 18.82.

Taxes

Over the trailing twelve months, JW Pharmaceutical Corporation has paid 29.66B in income taxes, reflecting an effective tax rate of 29.31.

Stock Price Statistics

JW Pharmaceutical Corporation's stock has declined approximately -33.81902% over the past 52 weeks. The 50-day moving average sits at 48,810.00, while the 200-day moving average is 56,477.00.

Income Statement

Over the trailing twelve months, JW Pharmaceutical Corporation generated 789.95B in revenue and converted that into 71.52B in net income, yielding earnings per share of 3,092.82. EBITDA reached 106.03B, while operating income came in at 106.03B.

Balance Sheet

JW Pharmaceutical Corporation holds 66.32B in cash and equivalents against 54.12B in total debt, resulting in a net debt position of 11.55B. Total book value stands at 284.56B, with working capital of 97.54B providing operational flexibility.

Cash Flow

JW Pharmaceutical Corporation produced 85.32B in operating cash flow over the past twelve months. After subtracting -34.43B in capital expenditures, free cash flow totaled 50.89B - equivalent to 2,200.41 per share.

Margins

JW Pharmaceutical Corporation operates with a gross margin of 47.29, reflecting its pricing power and cost economics. The operating margin of 13.42 and net profit margin of 9.05 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

JW Pharmaceutical Corporation's most recent stock split took place on December 27, 2023 with a 50:51 split ratio.

Scores

JW Pharmaceutical Corporation posts an Altman Z-Score of 6.09, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.